Clinical Trial Update: Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) [Phase 3]

View source ↗

Summary

The Phase 3 CREST-E trial evaluating creatine for Huntington's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Creatine (creatine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Huntington's Disease | Phase 3 | Status: TERMINATED